Bone Marrow-derived Mesenchymal Stem- cells for Treatment of Type 1 Diabetic Patients

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 834-867-Islet Biology
Bench to Bedside
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-867
Bagher Larijani*1, Ensieh Nasli2, Kamran Ali Moghaddam1, Nika Mojahed Yazdi1, Peyvand Amini3, Behrouz Nikbin Moghaddam1 and Ardeshir Ghavam Zadeh1
1Endocrinology and Metabolism Research Institute, Iran, 2Tehran University of Medical Sci, Tehran, Iran, 3Endocrinology and Metabolism Research Institute

Background: Mesenchymal stem cells (MSCs) are multipotent stem cells with immunomodulatory properties. In this study, we aimed to assess the safety and efficacy of MSCs transplantation in treatment of type 1 diabetes.

Methods: This clinical trial was performed on 23 type 1 diabetic patients aged 5-30 years. The patients had no serious medical diseases or operations with no history of DKA and acute infectious diseases and their fasting blood glucose levels (FBS) were less than 200 mg/dL. Anti glutamic acid decarboxylase test (Anti-GAD) was done for the diagnosis of type 1 diabetes. Culture expanded autologus mesenchymal cells were injected at the dosage of 2 million MSCs/kg .Patients who were still insulin dependent 6 months after the first injection, underwent a second injection of MSCs. Blood glucose and HbA1c levels were monitored throughout the study. No immunosuppressive agents were administered in the patients before and after the transplantation.

Results: No side effects were observed in the patients 19 months after the transplantation. The initial results indicated that 2 patients became insulin- independent within the 6 months after the first injection. In the group which underwent the second injection (n=21), two patients became insulin-free for 2 months but insulin-dependence relapsed after this period. No improvements in insulin dependency were observed in the rest of the patients in this group (n=19). One patient is still insulin free 19 months after the procedure with only one session of  MSCs injection.

Conclusion: The findings of this study demonstrated that MSCs transplantation may be considered as a novel curative treatment option for type 1diabetes the near future. However, clinical trials with larger cohorts and long- term follow-ups are essential to demonstrate the safety and effectiveness of this novel treatment option.

Nothing to Disclose: BL, EN, KAM, NM, PA, BN, AG

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

<< Previous Abstract | Next Abstract